Genomic Health announces positive results of Oncotype DX in colon cancer Genomic Health announced results from three studies of the Oncotype DX Colon Cancer test at the 2013 Gastrointestinal Cancers Symposium, including new data demonstrating that Recurrence Score results changed treatment recommendations in 45% of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis suggesting that use of the test may result in a significant reduction in direct medical costs and improve patient well-being.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Subscribe for More Information
